Zenith Drugs Stock Screener | Share Price & Fundamental Analysis
ZENITHDRUG
Pharmaceuticals
Screen Zenith Drugs share price with our stock screener - analyze fundamentals and track trades in your journal
Market Cap
₹88.83 Cr.
P/B Ratio
1.38
EPS (TTM)
₹5.63
Dividend Yield
-
Debt to Equity
0.63
52W High
-
52W Low
-
Operating Margin
-
Profit Margin
-
EBITDA
-
Net Income
-
Total Assets
₹135.00
Total Equity
₹62.00
Zenith Drugs Share Price History - Stock Screener Chart
Screen ZENITHDRUG historical share price movements with interactive charts. Analyze price trends and patterns.
Zenith Drugs Company Profile - Fundamental Screener
Screen Zenith Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ZENITHDRUG shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0QWN01013
Zenith Drugs Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen ZENITHDRUG balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Assets | |||
| Total Assets | 135 | 98 | 69 |
| Current Assets | 113 | 84 | 54 |
| Fixed Assets | 11 | 12 | 11 |
| Liabilities | |||
| Total Liabilities | 135 | 98 | 69 |
| Current Liabilities | 9 | 9 | 10 |
| Non-Current Liabilities | 0 | 0 | 0 |
| Shareholders' Equity | |||
| Total Equity | 62 | 18 | 12 |
| Share Capital | 17 | 0 | 0 |
| Reserves & Surplus | 45 | 17 | 12 |
Screen ZENITHDRUG income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2024-March | 2023-March | 2022-March |
|---|---|---|---|---|
| Revenue | 0 | 134 | 116 | 93 |
| Expenses | 0 | 115 | 106 | 85 |
| EBITDA | 0 | 19 | 10 | 8 |
| Operating Profit % | 0.00% | 13.00% | 8.00% | 7.00% |
| Depreciation | 0 | 1 | 1 | 1 |
| Interest | 0 | 3 | 2 | 2 |
| Profit Before Tax | 0 | 13 | 7 | 4 |
| Tax | 0 | 4 | 2 | 1 |
| Net Profit | 0 | 10 | 5 | 3 |
| EPS | 0.00 | 5.63 | 122.02 | 78.22 |
Zenith Drugs Cash Flow Screener - Liquidity Fundamentals
Screen ZENITHDRUG cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2024-March | 2023-March | 2022-March |
|---|---|---|---|
| Operating Activities | -13 | -5 | 5 |
| Investing Activities | 26 | 0 | -5 |
| Financing Activities | -5 | 5 | 1 |
| Net Cash Flow | 9 | 0 | 1 |
Screen ZENITHDRUG shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Sept | 2024-Feb | 2024-Mar | 2024-Sept | 2023-Sept |
|---|---|---|---|---|---|---|
| Promoter Holding | 69.98% | 69.98% | 100.00% | 69.98% | 69.98% | 100.00% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 25.56% | 25.25% | 0.00% | 15.20% | 25.57% | 0.00% |
| Other Holding | 4.46% | 4.77% | 0.00% | 14.83% | 4.45% | 0.00% |
| Shareholder Count | 1,544 | 1,466 | 7 | 1,117 | 1,355 | 7 |
Zenith Drugs Dividend Screener - Share Yield Analysis
Screen ZENITHDRUG dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.50 | 0.70% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
| 2016-March | ₹0.00 | 0.00% |
Zenith Drugs Index Membership - Market Screener Classification
Screen ZENITHDRUG by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Zenith Drugs Market Events Screener - Corporate Actions
Screen ZENITHDRUG market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 0.50 /share | 107.89% | ||
| Annual General Meeting | NA | 17.15% | ||
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -4.67% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | 0.76% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -6.06% |
Zenith Drugs Competitors Screener - Peer Comparison
Screen ZENITHDRUG competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,998 | 39.35 | 54,729 | 9.71% | 10,980 | 39.06 |
| Divis Laboratories | 169,648 | 68.64 | 9,712 | 18.67% | 2,191 | 44.96 |
| Torrent Pharmaceuticals | 129,394 | 60.42 | 11,539 | 6.99% | 1,911 | 59.35 |
| Cipla | 120,891 | 22.17 | 28,410 | 7.12% | 5,291 | 42.76 |
| Dr Reddys Laboratories | 105,564 | 18.42 | 33,741 | 16.73% | 5,725 | 49.97 |
| Lupin | 95,243 | 21.87 | 22,910 | 13.74% | 3,306 | 50.10 |
| Zydus Life Science | 91,743 | 18.03 | 23,511 | 18.55% | 4,615 | 34.06 |
| Mankind Pharma | 90,103 | 50.11 | 12,744 | 20.90% | 2,007 | 40.67 |
| Aurobindo Pharma | 68,657 | 20.16 | 32,346 | 9.43% | 3,484 | 46.33 |
| Alkem Laboratories | 65,803 | 26.89 | 13,458 | 3.70% | 2,216 | 37.45 |
Zenith Drugs Company Announcements - News Screener
Screen ZENITHDRUG latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.